Runda Medical 300 million yuan to acquire North China IVD dealers: enter the Beijing market

Runda Medical intends to acquire a 60% stake in Beijing Southeast held by Deqing Yangshuo with a transaction amount of RMB 31.326 million.

Acquisition of important distributors in North China, the acquisition has a certain premium. Southeast Beijing is one of the major in vitro diagnostic product circulation and service companies in Beijing. It mainly provides customers with in vitro diagnostic products such as Abbott, Sekisui and Bole. After more than ten years of development, its customers include Beijing and surrounding areas. Hundreds of large and medium-sized medical institutions are the most competitive in vitro diagnostic circulation and service enterprises in North China. In 2015, it achieved operating income of RMB 427.40 million and net profit of RMB 37.07 million. From January to November 2016, it realized operating income of RMB 452.31 million and net profit of RMB 40.26 million. The original shareholders of the southeast of Beijing promised that the net non-profit profits of Beijing Southeast from 2016 to 2018 were not less than RMB 28 million, RMB 53.75 million and RMB 61,187,500 respectively. Based on the non-net profit of the 2017 commitment, the acquisition premium PE is 9.71. According to the future growth trend of Beijing's southeast business and industry, the acquisition will be given a corresponding premium.

Earnings Forecast: As a leading provider of medical laboratories based in East China and radiating across the country, the company has opened a new “channel + technology” and “technology + platform” cooperation mode in the rapid development of the national layout, opening up a new situation of regional development. We continue to be optimistic about the company's future high-quality "national channel + independent products" development model, long-term optimistic about the company's sustainable development in the field of independent laboratories and the future space of emerging businesses. The company's three-year additional issue price of 28.80 yuan, providing a certain margin of safety, we expect the company's 2016-2018 EPS is 0.40, 0.58, 0.73 yuan, corresponding to the valuation of 76, 52 and 42 times, If we consider this merger and acquisition, we expect the company's EPS for 2017-2018 to be 0.64 and 0.85 yuan respectively, maintaining the “overweight” rating for the company.

Calcium Ethoxide CAS No.2914-17-2

Calcium Ethoxide Basic Information
CAS: 2914-17-2
MF: C4H10CaO2
MW: 130.2
EINECS: 220-828-8
Mol File: 2914-17-2.mol
Calcium Ethoxide Chemical Properties
Melting point >170°C (dec.)
Safety Information
Risk Statements 11-14-36

Safety Statements 8-16-26-43

Calcium Ethanoate,Calcium Ethanoate And Ethanol,Calcium Ethanoate Formula,Calcium Ethanoate And Ethanol Reaction,Calcium Ethanoate Balanced Equation,Calcium Ethanoate Bonding

Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com